Aprotinin

From Wikipedia, the free encyclopedia


Aprotinin
Systematic (IUPAC) name
Aprotinin
Identifiers
CAS number	9087-70-1
ATC code	B02 AB01
PubChem	N/A
Chemical data
Formula	C₂₈₄H₄₃₂N₈₄O₇₉S₇
Mol. weight	6511.51
Synonyms	trasylol, bovine pancreatic trypsin inhibitor
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	X
Legal status	RX/POM
Dependence Liability	none
Routes	intravenous

Aprotinin (Trasylol®, Bayer) is medication administered by injection used to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss.

1 Chemistry
2 Mechanism of action
3 Efficacy
4 Safety
5 In vitro use
6 History
7 References
8 External links

[edit] Chemistry

Aprotinin is a single-chain polypeptide derived from bovine lung tissue; it has a molecular weight of 6512 and consists of 16 different amino acids arranged in a chain of 58 amino acid residues.

The stability of the molecule is due to the 3 disulphide bridges linking the 6 cysteine members of the chain. The lysine (15)-alanine (16) sequence on this strongly basic polypeptide represents the active centre.

Aprotinin is a single-chain polypeptide derived from bovine lung tissue; it has a molecular weight of 6512 and consists of 16 different amino acids arranged in a chain of 58 amino acid residues.

[edit] Mechanism of action

Aprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml^[1]. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis^[2].

Aprotinin is a single-chain polypeptide derived from bovine lung tissue; it has a molecular weight of 6512 and consists of 16 different amino acids arranged in a chain of 58 amino acid residues.

[edit] Efficacy

In cardiac surgery with a high risk of significant blood loss, aprotinin significantly reduced bleeding, mortality and hospital stay^[1]. Beneficial effects were also reported in high-risk orthopedic surgery^[1]. In liver transplantation, initial reports of benefit were overshadowed by concerns about toxicity^[3].

In a meta-analysis performed in 2004, transfusion requirements decreased by 39% in coronary artery bypass graft (CABG) surgery^[4]. In orthopedic surgery, a decrease of blood transfusions was likewise confirmed^[5].

[edit] Safety

There have been concerns about the safety of aprotinin^[1]. Anaphylaxis (a severe allergic reaction) occurs at a rate of 1:200 in first-time use, but serology (measuring antibodies against aprotinin in the blood) is not carried out in practice to predict anaphylaxis risk because the correct interpretation of these tests is difficult.^[1]

Thrombosis, presumably from overactive inhibition of the fibrinolytic system, may occur at a higher rate, but until 2006 there was limited evidence for this association^[1]^[4]. Similarly, while biochemical measures of renal function were known to occasionally deteriorate, there was no evidence that this greatly influenced outcomes^[1]. A study performed in cardiac surgery patients reported in 2006 showed that there was indeed a risk of acute renal failure, myocardial infarction and heart failure, as well as stroke and encephalopathy^[6] The study authors recommend older antifibrinolytics (such as tranexamic acid) in which these risks were not documented^[6].

In September 2006, Bayer A.G. was faulted by the FDA for not revealing during testimony the existence of a commissioned retrospective study of 67,000 patients, 30,000 of whom received Trasylol and the rest other anti-fibrinolytics. The study concluded Trasylol carried greater risks. The FDA was alerted to the study by one of the researchers involved. Although the FDA issued a statement of concern they did not change their recommendation that the drug may benefit certain subpopulations of patients.^[7] In a Public Health Advisory Update dated October 3, 2006, the FDA recommended that "physicians consider limiting Trasylol use to those situations in which the clinical benefit of reduced blood loss is necessary to medical management and outweighs the potential risks" and carefully monitor patients. ^[8]

On October 29, 2006 the Food and Drug Administration issued a warning that aprotinin may have serious kidney and cardiovascular toxicity. The producer, Bayer, reported to the FDA that additional observation studies showed that it may increase the chance for death, serious kidney damage, congestive heart failure and strokes. FDA warned clinicians to consider limiting use to those situations where the clinical benefit of reduced blood loss is essential to medical management and outweighs the potential risks.^[9]

No cases of bovine spongiform encephalopathy transmission by aprotinin have been reported, although the drug was withdrawn in Italy due to fears of this ^[1].

[edit] In vitro use

Small amounts of aprotinin can be added to tubes of drawn blood to enable laboratory measurement of certain rapidly degraded proteins such as glucagon.

[edit] History

Initially named "kallikrein inactivator", aprotinin was first isolated from cow parotid glands in 1928^[10] and independently as "bovine pancreatic trypsin inhibitor" from cow pancreas in 1936.^[11] It was purified from bovine lung in 1964.^[12] As it inhibits pancreatic enzymes, it was initially used in the treatment for acute pancreatitis, in which destruction of the gland by its own enzymes is thought to be part of the pathogenesis.^[13] Its use in major surgery commenced in the 1960s.^[14]

[edit] References

^ ^a ^b ^c ^d ^e ^f ^g ^h
^
^ Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 2005;11:10-8. PMID 15690531.
^ ^a ^b Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8. PMID 15354106.
^ Shiga T, Wajima Z, Inoue T, Sakamoto A. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesth Analg 2005;101:1602-7. PMID 16301226.
^ ^a ^b Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65. PMID 16436767.
^ Gardiner Harris. F.D.A. says Bayer Failed to Reveal Drug Risk Study. New York Times; September 30, 2006
^ Trasylol Public Health Advisory Update; October 3, 2006
^ U.S. Food and Drug Administration. Information for Healthcare Professionals; Aprotinin (marketed as Trasylol). Retrieved on 2006-10-30.
^ Kraut H, Frey EK, Bauer E. Z Physiol Chem 1928;175:97-114.
^ Kunitz M, Northrup J. Isolation from beef pancreas of crystalline trypsinogen, trypsin, trypsin inhibitor, and an inhibitor trypsin compound. J Gen Physiol 1936;19:991-1007. PDF.
^ Kraut H, Bhargava N. Versuche zur Isolierung des Kallikrein-Inaktivators aus Rinderlunge and seine Identifizierung mit dem Inaktivator aus Rinderparotis. Z Physiol Chem 1964;328:231-7. PMID 14330402.
^ Nugent FW, Warren KW, Jonasson H, Garciadeparedes G. Early experience with trasylol in the treatment of acute pancreatitis. South Med J 1964;57:1317-21. PMID 14195953.
^ Tice DA, Worth Jr MH, Clauss RH, Reed GH. The inhibition of trasylol of fibrinolytic activity associated with cardiovascular operations. Surg Gynecol Obstet 1964;119:71-4. PMID 14179354.